German China

The Netherlands: Biopharmaceuticals Halix to Start Operational Production at New cGMP Facility

Editor: MA Alexander Stark

Halix, a contract development and manufacturing organization of clinical and commercial proteins and viral products, based in the Netherlands, announced the interim delivery of a new 6,700 m2 cGMP facility in Leiden Bio Science Park.

The new cGMP facility will be starting operational production in Q4-2019.
The new cGMP facility will be starting operational production in Q4-2019.
(Source: Halix)

Leiden/The Netherlands — Following one year of construction, Halix has completed its new state-of-the-art cGMP facility for the development and production of biopharmaceutical drug substances.

The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000 Liter single-use bioreactors. In addition, lab space is available for process development, analytical development and quality control. All cleanroom areas have a unidirectional process flow and are designed to allow commercial manufacturing of biopharmaceuticals products.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent